A new research paper titled "A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850" has been published in Oncotarget.
Apr 12, 2023
0
22
Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular ...
Apr 22, 2017
0
2
A KAIST research team presented a novel method for improving medication treatment for liver cancer using Systems Biology, combining research from information technology and the life sciences.
Aug 31, 2017
0
0
Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates, regardless of whether ...
Apr 21, 2017
0
1
The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy (SIRT) ...
Apr 13, 2018
0
2
Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), ...
Nov 9, 2015
0
2
Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone ...
Jun 11, 2012
0
0
A study led by the researcher at the Institute of Biomedical Research (IDIBELL), Isabel Fabregat, could serve to select patients with hepatocellular carcinoma unresponsive to most frequently used drug in liver cancer: sorafenib. ...
Oct 23, 2014
0
0
(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.
Oct 13, 2015
0
7
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec ...
Apr 10, 2013
0
0
